Comparative Outcomes of Robotic Radical Prostatectomy in Patients with Locally Advanced Prostate Cancer

Abstract

The effectiveness of radical prostatectomy alone for locally advanced prostate cancer is controversial owing to an increased complication rate and treatment-related morbidity. With technical advances and refinements in surgical techniques, robotic-assisted radical prostatectomy (RARP) has improved the outcomes of patients with locally advanced prostate cancer. RARP therefore plays a role in the treatment of locally advanced prostate cancer. In this study, we enrolled a total of 76 patients with pathologic stage pT3a, pT3b, pT4, or pN1. All patients were followed from surgery to June 2022, and their characteristics, perioperative outcomes, complications, adjuvant therapies and outcomes were analyzed. The median age of the patients was 69 years, and the initial PSA level was 20.5 (IQR 10.8–31.6) ng/mL. The median operative time was 205 (IQR 182–241) minutes. Sixty-six patients (86.8%) regained continence within 1 year, and the continence rate within 3 years of follow-up was 90.8% (69 patients). The overall survival rate was 100%. Twenty-two patients had BCR, of whom 13 received salvage androgen deprivation therapy (ADT), 2 received salvage external beam radiation therapy (EBRT) alone, and 7 received combined ADT and EBRT. No patient had disease progression to castration-resistant prostate cancer during a median 36 months of follow-up after salvage therapy. Our results suggest that RARP can also decrease tumor burden and allow for accurate and precise pathological staging with the need for subsequent treatment. Therefore, we recommend that RARP represents a well-standardized, safe, and oncologically effective option for patients with locally advanced prostate cancer.

Real‑world retrospective study of early‑stage prostate cancer at a Portuguese Comprehensive Cancer Centre: The PEarlC study

“…There is likely a judicious use of surgery as a single recommendation for high-risk patients, mainly because most of the time there is a need for multimodal treatments, and this is of the utmost importance to the multidisciplinary board of IPO Porto. There is still a discussion about the use of radical prostatectomy as a first-line treatment for LAPC ( 28 ). At IPO Porto, only 4.5% (n=5) of patients with LAPC were submitted to this type of surgery.…”

“…----------------------------------------------------------------------------- multidisciplinary board of IPO Porto. There is still a discussion about the use of radical prostatectomy as a first-line treatment for LAPC (28). At IPO Porto, only 4.5% (n=5) of patients with LAPC were submitted to this type of surgery.…”